-+ 0.00%
-+ 0.00%
-+ 0.00%

Fujian Haixi Pharma wins FDA IND clearance for HX9428 Phase II nAMD trial

PUBT·08/04/2026 09:13:00
Listen to the news
Fujian Haixi Pharma wins FDA IND clearance for HX9428 Phase II nAMD trial
  • Fujian Haixi Pharmaceuticals secured US FDA IND clearance to start a Phase II trial of oral nAMD candidate HX9428 in the US.
  • China launched a separate Phase II study (CTR20262884) versus Regeneron’s aflibercept, targeting 60 patients across multiple sites.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fujian Haixi Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260804-12271079), on August 04, 2026, and is solely responsible for the information contained therein.